An Open-label Phase Ib/II Study of Avelumab in Combination with
5-azacytidine (Vidaza) for the Treatment of Patients with
Refractory/Relapsed Acute Myeloid Leukemia

This clinical research study has 2 parts: Part A and Part B. The goal
of Part A is to find the highest tolerable dose of avelumab that can be
given in combination with 5-azacytidine to patients with relapsed or
refractory AML. The goal of Part B is to learn if the highest tolerable
dose of this drug combination found in Part A can help to control the
disease. The safety of this drug combination will also be studied in
both parts of the study.